Get startedLog in
    Picture of Royalty Pharma logo

    RPRX — Royalty Pharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo

    Picture of Royalty Pharma logoRoyalty Pharma
    11/01/2026 22:16
    Jan 11 (Reuters) - Royalty Pharma PLC RPRX.O:

TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCELERATE DEVELOPMENT OF POTENTIAL TREATMENT FOR VITILIGO

TEVA - TEVA TO SHARE TEV-'408 TRIAL RESULTS IN 2026

ROYALTY PHARMA  - TO PROVIDE UP TO $500 MILLION FOR TEVA'S TEV-'408

ROYALTY PHARMA : TEV-'408 IS CURRENTLY IN PHASE 1B FOR TREATMENT OF VITILIGO AND IN PHASE 2A FOR CELIAC DISEASE

Source text: ID:nGNXbWXSwh

Further company coverage: RPRX.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Royalty Pharma

    See all news